Efflux Pharma Contact
About

A clinical-stage
biotechnology company

Efflux Pharma has a deep understanding of the de novo and acquired drug-resistance mechanisms that limit the efficacy of oncology treatment, and a lead compound designed to restore drug sensetivity.

Overview

Designed to make existing drugs work harder

Efflux Pharma is a clinical-stage biotechnology company with deep understanding of de novo or acquired drug-resistance mechanisms in oncology treatments.

Its lead compound SCO-101 has a novel triple-acting mode of action and is used as a combination partner with anti-cancer drugs — for example chemotherapy — in the treatment of cancers.

SCO-101 inhibits

1

ABCG2

Drug efflux pump

Traps cytotoxic chemotherapy inside the cancer cell, raising its intracellular concentration.

2

UGT1A1

Metabolising enzyme

Inhibiting UGT1A1 slows the clearance of SN-38, the active metabolite of irinotecan.

3

SRPK1

Kinase

Targets a driver of endocrine-treatment resistance in cancer.

Founder · Scientific lead
Leadership

Nils Brünner

MD, DMSc · Professor Emeritus, University of Copenhagen

The team behind Efflux Pharma is led by Nils Brünner — co-founder of Scandion Oncology A/S, which completed the first pre-clinical and clinical trials of SCO-101.

Nils has 15 years of training in internal medicine and oncology, and more than 30 years of experience within translational cancer research. With additional education in cell and molecular biology from the USA, he served as Center Director of a Danish National Research Foundation centre (Grundforskningsfonden) focused on anti-cancer drug resistance. He has published more than 375 scientific papers, mostly dealing with translational cancer research.

Contact

Let's talk

For partnering, investment and scientific enquiries.

Email
nbr@effluxpharma.com
Web
effluxpharma.com
Focus
Overcoming drug resistance in oncology

Efflux Pharma works with clinical partners and investors to bring SCO-101 to the patients who need it most — those who have exhausted standard treatment options.

Get in touch View the pipeline